February 9, 2026
Meet Irma Mahmutovic Persson - In Vivo Imaging Specialist at LBIC
In this edition of our Meet the Nodes interview series, we introduce Irma Mahmutovic Persson, staff researcher at the Lund BioImaging Centre (LBIC),…

Euro-BioImaging is pleased to inform its community about the EP PerMed Fast Track Validation Programme, a funding opportunity designed to advance personalised medicine solutions towards clinical application and market readiness.
The Programme aims to overcome bottlenecks in the technology development by giving developers access to specialised validation centres, which provide the necessary infrastructure and expertise, for rigorous testing of new technology and concepts. This way, developers can ensure innovations meet the needs and expectations of end-users, including clinicians and patients.
Euro-BioImaging Nodes can play a pivotal role in this programme by partnering with applicants as validation centres. The Nodes can provide access to advanced imaging expertise, cutting-edge instruments, image data, and AI-driven tools supporting the validation of a wide range of personalised medicine innovations.
Key details:
For our Nodes, this is an opportunity to:
In selected projects, the applicants and their chosen validation centres, which could be Euro-BioImaging Node facilities, collaborate to create detailed project plans for the validation, ensuring the successful execution of their studies. At least 70% of the funding must be allocated to validation services.
This programme is open to start-ups and researchers from EU Member States or Horizon Europe-associated countries who have personalised medicine solutions at proof-of-concept stage or higher (TRL3+).
For more information about the call and eligibility criteria, visit the EP PerMed Fast Track Call page.
Don’t miss this chance to advance personalised medicine innovations with Euro-BioImaging’s expertise!
February 9, 2026
In this edition of our Meet the Nodes interview series, we introduce Irma Mahmutovic Persson, staff researcher at the Lund BioImaging Centre (LBIC),…
February 3, 2026
There’s a new marine sample dataset on the BioImage Archive, thanks to Tina Wiegand and her colleagues, part…
February 3, 2026
Breast cancer remains one of the most common cancers worldwide, and HER2-positive tumours — characterised by overexpression of the HER2 receptor — are known…